In addition to ALCL, ALK auto-antibodies have been detected in ALK-positive NSCLC patients (62%; 13/21 cases), in lymphoma patients with ALK-translocation unrelated to NPM-ALK (59%; 13/22 cases), in one ALK-positive rhabdomyosarcoma patient, as well as in an ALK-WT neuroblastoma patient [28]. This evidence concerns the gene ALK and neuroblastoma.